The drug could be used in all kinds of hepatitis C
patients, Liang said, and could help prevent re-infection in
patients who undergo liver transplantation.
The research is early, and a number of challenges remain, however. For one thing, "we would have to use the currently accepted dosing for any clinical trial, because the drug at high doses may have significant side effects, such as drowsiness," Liang said.